In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

For treatment, injections deliver a monoclonal antibody to stop the growth of the blood vessels. The hope is that this allows ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Meibomian gland dysfunction assessments in children a highlight at the Tear Film & Ocular Surface Society's 2024 meeting.

Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...